Legalny chiński dostawca sterydów

Postać proszku peptydowego

» Hormon Chemiczny » Hormon peptydowy » Postać proszku peptydowego

Lanreotyd API w postaci proszku CAS 108736-35-2

99% Lanreotide Peptides for Muscle Fitness ,Neuroendocrine Tumors /Antitumor Agent,Body-building.

zapytanie
  • Specyfikacje

Lanreotyd API w postaci proszku CAS 108736-35-2

Lanreotyd API w postaci proszku CAS 108736-35-2

Lanreotide CAS 108736-35-2

Opis produktu
Important Notification: All of our products and services listed in this website are for research or production use only, not for direct human use.
Raw powder Lanreotide 108736-35-2

Synonimy: LANREOTIDE;AUTOGEL;BETA-(2-NAPHTHYL)-D-ALA-CYS-TYR-D-TRP-LYS-VAL-CYS-THR AMIDE;BIM-23014;ANGIOPEPTIN;H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2;H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2, (DISULFIDE BOND);IPSTYL
MF: C54H69N11O10S2
MW: 1096.32
CAS:108736-35-2
Analiza:98%
Wygląd:biały proszek

Lanreotide——-Pharmacology

Lanreotide is a synthetic analogue of somatostatin, a naturally occurring inhibitory hormone which blocks the release of several other hormones, including growth hormone, thyroid-stimulating hormone (TSH), insulin and glucagon. Lanreotide binds to the same receptors as somatostatin, although with higher affinity to peripheral receptors, and has similar activity. Jednakże, while somatostatin is quickly broken down in the body (within minutes), lanreotide has a much longer half-life, and produces far more prolonged effects.The efficacy of lanreotide has not been extensively studied, and results differ greatly between trials and formulations.

Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Its sequence is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2.

Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) on August 30, 2007.

Lanreotide——-Indications

Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma, a rare tumor of the pituitary gland which secretes.

Lanreotide also shows activity against non-endocrine tumors, oraz, along with other somatostatin analogues, is being studied as a possible general antitumor agent.

Lanreotide ,In Dec 2014 the US FDA approved lanreotide for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Lanreotide——-Side effects

Lanreotide ,The main side effects of lanreotide treatment are mild to moderate pain at the injection site and gastrointestinal disturbances, such as diarrhea, nausea and vomiting. Isolated cases of gallstone formation have been associated with use of lanreotide, particularly over long periods of time.

 

KATEGORIA I TAGI:
Postać proszku peptydowego , , , , ,

formularz zapytania ( skontaktujemy się z tobą tak szybko, jak to możliwe )

Nazwa:
*
E-mail:
*
Wiadomość:

Weryfikacja:
4 + 8 = ?

Może też lubisz

  • Kategorie produktów

  • Udostępnij znajomemu

  • Sieci Bitcoina

    znak bitowy
    baza monet
    moneta
    lokalne bitcoiny
    rynek bitcoinów

  • Skontaktuj się z nami

    Whatsapp&Telegram:

    Sieć:www.aaspharm.com


    jesse@aaspharm.com